limbic encephalitis with LGI1 antibodies

Summary

limbic encephalitis with LGI1 antibodies (MONDO:0015592) is a disease and 1 clinical trial. A subtype of postinfectious encephalitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	limbic encephalitis with LGI1 antibodies
Mondo ID	MONDO:0015592
Orphanet	163908
SNOMED CT	763794005
UMLS	C4706583
MedGen	1645969
GARD	0013406
Is cancer (heuristic)	no

Also known as: limbic encephalitis with leucine-rich glioma-inactivated 1 antibodies

Disease family

This is a subtype of postinfectious encephalitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › encephalomyelitis › encephalitis › infectious encephalitis › postinfectious encephalitis › limbic encephalitis with LGI1 antibodies

Related subtypes (6): Rasmussen subacute encephalitis, Bickerstaff brainstem encephalitis, acute disseminated encephalomyelitis, encephalitis lethargica, steroid-responsive encephalopathy associated with autoimmune thyroiditis, rubella encephalitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06515106	Not specified	RECRUITING	Antibody-mediated LGI1 Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Chronic Phase of the Disease